Condition: Pseudomyxoma Peritonei · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The goal of this clinical trial is to evaluate the safety and efficacy of neoadjuvant capecitabine and cyclophosphamide treatment in patients affected by huge Pseudomyxoma peritonei (PMP) (peritoneal cancer index \>28). Treatment consists of metronomic (low-dose medication for a prolonged time) of capecitabine plus cyclophosphamide for 6 months followed by standard of care cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The main question the trial aims to answer is which is the proportion of patients with complete cytoreduction at CRS/HIPEC after neoadjuvant metronomic approach with oral capecitabine and cyclophosphamide in patients affected by huge PMP.
This description comes directly from the study's public registry record.
Alessandra Raimondi, MD · +39 02 2390 2581 · alessandra.raimondi@istitutotumori.mi.it
Shigeki Kusamura, MD · +39 02 2390 3441 · shigeki.kusamura@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06800391